Unpredictable outcome in lamivudine (LAM): resistant patients under high daily doses & early effects of combined therapy of lam plus pegylated interferon (2002)
- Authors:
- USP affiliated authors: SILVA, LUIZ CAETANO DA - FM ; NITA, SUZANE KIOKO ONO - FM ; CARRILHO, FLAIR JOSE - FM
- Unidade: FM
- Assunto: INTERFERONS
- Language: Inglês
- Imprenta:
- Conference titles: Therapy of viral hepatitis and prevention of hepatocellular carcinoma of First JSH Single Topic Conference
-
ABNT
SILVA, L. C. da et al. Unpredictable outcome in lamivudine (LAM): resistant patients under high daily doses & early effects of combined therapy of lam plus pegylated interferon. 2002, Anais.. Yamanashi: Faculdade de Medicina, Universidade de São Paulo, 2002. . Acesso em: 18 nov. 2024. -
APA
Silva, L. C. da, Nita, S. K. O., Pinho, J. R. R., & Carrilho, F. J. (2002). Unpredictable outcome in lamivudine (LAM): resistant patients under high daily doses & early effects of combined therapy of lam plus pegylated interferon. In . Yamanashi: Faculdade de Medicina, Universidade de São Paulo. -
NLM
Silva LC da, Nita SKO, Pinho JRR, Carrilho FJ. Unpredictable outcome in lamivudine (LAM): resistant patients under high daily doses & early effects of combined therapy of lam plus pegylated interferon. 2002 ;[citado 2024 nov. 18 ] -
Vancouver
Silva LC da, Nita SKO, Pinho JRR, Carrilho FJ. Unpredictable outcome in lamivudine (LAM): resistant patients under high daily doses & early effects of combined therapy of lam plus pegylated interferon. 2002 ;[citado 2024 nov. 18 ] - High resistance to therapy in cirrhotic patients carrying HCV-RNA genotype 3
- High resistance to therapy in cirrhotic patients carrying HCV RNA genotype 3.
- Rapid and profound drop HCV RNA viremia induced by high dose of consensus IFN (CIFN) just before starting pegylated interferon (PEG-IFN) plus ribavirin (RBV) in chronic hepatitits C patients (pts) previously resistant to combined therapy (IFN+RBV): preliminary report
- Unpredictable outcome in lamivudine (LAM): resistant patients under high daily doses & early effects of combined therapy of lam plus pegylated interferon
- Cinética viral e resultados tardios do tratamento com consensus interferon a (CIFN) e ribavirina (RB) em pacientes com hepatite crônica C (HC-C) previamente resistentes à associação com IFN a e RB
- High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study
- A twelve-week period of follow-up after an end of treatment response (ETR) in patients with chronic hepatitis C (CH-C) submitted to combined therapy is a reliable period to characterize a sustained response
- Tratamento da hepatite C
- Rapid and profound drop of HCV RNA viraemia induced by high dose of consensus interferon just before starting pegylated interferon plus ribavirin in chronic hepatitis C patients previously resistant to combined therapy:: preliminary report.
- A twelve-week period of follow-up after an end-of-treatment response in patients with chronic hepatitis C submitted to combined therapy is a reliable period to characterize a sustained response.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
